Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vonoprazan · Voquezna

Small molecule · Inhibitor of H+/K+ ATPase (gastric proton pump) (ATP4A) · developed by Phathom

Approved FDA, Nov 2023
PHAT Developer
2 Registered trials

What is Vonoprazan?

Vonoprazan is a potassium-competitive acid blocker that concentrates in gastric parietal cells and reversibly binds the potassium-binding site of the H+/K+ ATPase proton pump, inhibiting the final step of gastric acid secretion. It is studied in symptomatic non-erosive gastroesophageal reflux disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Voquezna
Drug type
Small molecule
Targets
H+/K+ ATPase (gastric proton pump) (ATP4A)
Mechanism
Inhibitor of H+/K+ ATPase (gastric proton pump) (ATP4A)
Pathways
gastric acid secretion
Therapy area
Gastroenterology
Developer
Phathom (PHAT)
FDA status
Approved as Voquezna (November 1, 2023), NDA215151 · FDA label
UNII
1R5L3J156G

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07752407 Phase 3 Symptomatic Non-erosive Gastroesophageal Reflux Disease Recruiting PHAT
NCT06831344 Phase 1 Healthy Volunteers Completed PHAT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Symptomatic Non-erosive Gastroesophageal Reflux DiseaseHealthy Volunteers

Other drugs acting on ATP4A

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAT page.

Follow PHAT, the company behind Vonoprazan

See PHAT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHAT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.